Clinical	O
study	O

Patients	O

The	O
study	O
was	O
initially	O
designed	O
as	O
a	O
multi	O
-	O
center	O
study	O
across	O
hospitals	O
in	O
Changsha	O
city	O
and	O
in	O
other	O
cities	O
of	O
Hunan	O
Province	O
,	O

China	O
.	O

However	O
,	O
per	O
a	O
government	O
order	O
,	O
all	O
patients	O
from	O
hospitals	O
in	O
Changsha	O
city	O
had	O
to	O
be	O
relocated	O
to	O
the	O
First	O
Hospital	O
of	O
Changsha	O
,	O
a	O
designated	O
treatment	O
center	O
for	O
all	O
COVID	O
-	O
19	O
patients	O
in	O
Changsha	O
city	O
,	O
and	O
hospitals	O
in	O
other	O
cities	O
of	O
Hunan	O

Province	O
were	O
not	O
able	O
to	O
participate	O
due	O
to	O
various	O
reasons	O
.	O

The	O
study	O
was	O
changed	O
to	O
a	O
single	O
-	O
center	O
study	O
.	O

This	O
study	O
was	O
approved	O
by	O
the	O
ethics	O
committee	O
of	O
the	O
First	O
Hospital	O
of	O
Changsha	O
(	O
file	O
number	O
KX	O
-	O
2020002	O
)	O
and	O
was	O
conducted	O
at	O
the	O
hospital	O
.	O

The	O
study	O
was	O
also	O
registered	O
in	O
the	O
Chinese	O
Clinical	O
Trial	O
Registry	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
chictr	O
.	O
org	O
.	O
cn	O
/	O
)	O
,	O
number	O
ChiCTR2000029496	O
.	O

Hospitalized	O
COVID	O
-	O
19	O
patients	O
with	O
confirmed	O
SARS	O
-	O
CoV	O
-	O
2	O
detection	O
,	O
clinically	O
classified	O
as	O
moderate	O
or	O
severe	O
,	O
at	O
an	O
age	O
over	O
18	O
years	O
,	O
and	O
without	O
comorbidity	O
of	O
severe	O
heart	O
,	O
lung	O
,	O
or	O
brain	O
diseases	O
,	O
were	O
eligible	O
for	O
enrolling	O
into	O
this	O
study	O
.	O

Moderate	O
patients	O
were	O
defined	O
as	O
“	O
patients	O
with	O
fever	O
,	O
symptoms	O
of	O
the	O
respiratory	O
system	O
and	O
pneumonia	O
changes	O
in	O
CT	O
images	O
,	O
and	O
severe	O
patients	O
were	O
defined	O
as	O
“	O
patients	O
with	O
any	O
of	O
the	O
following	O
:	O
(	O
1	O
)	O
Respiratory	O
distress	O
,	O
respiratory	O
frequency	O
	O
30	O
/	O
min	O
;	O
(	O
2	O
)	O
Under	O
rest	O
status	O
,	O
arterial	O
oxygen	O
saturation	O
(	O
SaO2	O
)	O
	O
93	O
%	O
;	O
(	O
3	O
)	O
Arterial	O
partial	O
pressure	O
of	O
oxygen	O
(	O
PaO2	O
)	O
/	O
fraction	O
of	O
inspired	O
oxygen	O
(	O
FiO2	O
)	O
	O
300	O
mmHg	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
observe	O
moderate	O
and	O
severe	O
COVID	O
-	O
19	O
patients	O
as	O
these	O
patients	O
would	O
likely	O
benefit	O
more	O
from	O
antiviral	O
treatments	O
.	O

Trial	O
design	O
and	O
treatments	O

This	O
was	O
a	O
randomized	O
,	O
open	O
-	O
label	O
,	O
parallel	O
-	O
group	O
study	O
.	O

Patients	O
eligible	O
for	O
the	O
study	O
were	O
assigned	O
,	O
in	O
a	O
1	O
:	O
1	O
:	O
1	O
ratio	O
,	O
to	O

Novaferon	O
,	O
Novaferon	O
plus	O
Lopinavir	O
/	O
Ritonavir	O
,	O
or	O
Lopinavir	O
/	O

Ritonavir	O
group	O
.	O

An	O
SAS	O
generated	O
simple	O
randomization	O
schedule	O
was	O
prepared	O
by	O
a	O
statistician	O
not	O
involved	O
in	O
the	O
trial	O
.	O

Using	O
the	O
order	O
in	O
which	O
they	O
enrolled	O
in	O
the	O
study	O
,	O
patients	O
were	O
assigned	O
to	O
a	O
treatment	O
group	O
that	O
was	O
implemented	O
by	O
a	O
research	O
assistant	O
.	O

Informed	O
consent	O
was	O
obtained	O
from	O
all	O
enrolled	O
patients	O
.	O

Antiviral	O
effects	O
were	O
assessed	O
on	O
day	O
three	O
,	O
day	O
six	O
,	O
and	O
day	O
nine	O
after	O
starting	O
drug	O
administration	O
.	O

The	O
approved	O
dosage	O
of	O
Novaferon	O
for	O
hepatitis	O
B	O
application	O
is	O
the	O
daily	O
injection	O
of	O
10	O
mg	O
of	O
protein	O
in	O
1	O
.	O
0	O
ml	O
volume	O
per	O
vial	O
.	O

Lopinavir	O
/	O
Ritonavir	O
(	O
Kaletra	O
)	O
was	O
manufactured	O
by	O
AbbVie	O
Inc	O
.	O
;	O
each	O
tablet	O
contained	O
200	O
mg	O
of	O
Lopinavir	O
and	O
50	O
mg	O
of	O
Ritonavir	O
.	O

The	O
total	O
daily	O
doses	O
(	O
40	O
mg	O
)	O
of	O
Novaferon	O
were	O
administered	O
to	O
patients	O
twice	O
per	O
day	O
by	O
oxygen	O
-	O
driven	O
aerosolized	O
inhalation	O
for	O
15	O
min	O
of	O
20	O
mg	O
of	O
Novaferon	O
(	O
2	O
	O
1	O
ml	O
vials	O
)	O
diluted	O
with	O
saline	O
.	O

For	O
patients	O
receiving	O
Lopinavir	O
/	O
Ritonavir	O
(	O
Kaletra	O
)	O
,	O
two	O
tablets	O
were	O
orally	O
taken	O
twice	O
per	O
day	O
.	O

The	O
aerosolized	O
inhalation	O
was	O
administrated	O
to	O
hospitalized	O
patients	O
in	O
the	O
negative	O
-	O
pressure	O
wards	O
at	O
the	O
designated	O
COVID	O
-	O
19	O
center	O
to	O
minimize	O
the	O
risk	O
of	O
disease	O
transmission	O
.	O

Assessments	O

Samples	O
of	O
nasopharyngeal	O
swabs	O
on	B-TimeFrame
day	I-TimeFrame
three	I-TimeFrame
,	I-TimeFrame
day	I-TimeFrame
six	I-TimeFrame
,	I-TimeFrame
and	I-TimeFrame
day	I-TimeFrame
nine	I-TimeFrame
during	O
the	O
seven	O
to	O
ten	O
-	O
day	O
course	O
of	O
antiviral	O
treatment	O
were	O
collected	O
from	O
the	O
patients	O
and	O
tested	O
for	O
SARS	O
-	O
CoV	O
-	O
2	O
nucleic	O
acids	O
by	O
RT	O
-	O
PCR	O
.	O

SARS	B-OtherOutcome
-	I-OtherOutcome
CoV	I-OtherOutcome
-	I-OtherOutcome
2	I-OtherOutcome
clearance	I-OtherOutcome
in	I-OtherOutcome
COVID	I-OtherOutcome
-	I-OtherOutcome
19	I-OtherOutcome
patients	I-OtherOutcome
was	O
defined	O
as	O
two	B-OutcomeDefinition
consecutive	I-OutcomeDefinition
negative	I-OutcomeDefinition
-	I-OutcomeDefinition
detection	I-OutcomeDefinition
of	I-OutcomeDefinition
SARS	I-OutcomeDefinition
-	I-OutcomeDefinition
CoV	I-OutcomeDefinition
-	I-OutcomeDefinition
2	I-OutcomeDefinition
RNA	I-OutcomeDefinition
in	I-OutcomeDefinition
nasopharyngeal	I-OutcomeDefinition
swab	I-OutcomeDefinition
samples	I-OutcomeDefinition
with	I-OutcomeDefinition
an	I-OutcomeDefinition
interval	I-OutcomeDefinition
of	I-OutcomeDefinition
over	I-OutcomeDefinition
24	I-OutcomeDefinition
h	I-OutcomeDefinition
.	O

Adverse	B-OtherOutcome
events	I-OtherOutcome
were	O
monitored	O
throughout	O
the	O
trial	O
,	O
reported	B-OutcomeDefinition
and	I-OutcomeDefinition
graded	I-OutcomeDefinition
based	I-OutcomeDefinition
on	I-OutcomeDefinition
the	I-OutcomeDefinition
WHO	I-OutcomeDefinition
Toxicity	I-OutcomeDefinition
Grading	I-OutcomeDefinition
Scale	I-OutcomeDefinition
for	I-OutcomeDefinition
Determining	I-OutcomeDefinition
the	I-OutcomeDefinition
Severity	I-OutcomeDefinition
.	O

The	O
peak	O
levels	O
of	O
the	O
SARS	O
virus	O
were	O
around	O
ten	O
days	O
after	O
onset	O
,	O
and	O
then	O
the	O
viral	O
level	O
began	O
to	O
decrease	O
without	O
effective	O
antiviral	O
treatment	O
in	O
SARS	O
patients	O
(	O
Peiris	O
et	O
al	O
.	O
,	O
2003	O
)	O
.	O

Considering	O
the	O
homology	O
of	O
gene	O
sequences	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
and	O
SARS	O
was	O
over	O
90	O
%	O
(	O
Zhu	O
et	O
al	O
.	O
,	O
2020	O
)	O
,	O
we	O
assumed	O
that	O
the	O
intervention	O
of	O
antiviral	O
drugs	O
in	O
COVID	O
-	O
19	O
patients	O
would	O
likely	O
enhance	O
or	O
shorten	O
the	O
time	O
to	O
viral	O
clearance	O
.	O

In	O
this	O
regard	O
,	O
this	O
study	O
'	O
s	O
primary	O
endpoint	O
was	O
chosen	O
based	O
on	O
the	O
SARS	B-PrimaryOutcome
-	I-PrimaryOutcome
CoV	I-PrimaryOutcome
-	I-PrimaryOutcome
2	I-PrimaryOutcome
clearance	I-PrimaryOutcome
rates	I-PrimaryOutcome
in	O
COVID	O
-	O
19	O
patients	O
assessed	O
on	B-TimeFrame
day	I-TimeFrame
six	I-TimeFrame
of	I-TimeFrame
antiviral	I-TimeFrame
treatment	I-TimeFrame
.	O

The	O
secondary	O
endpoint	O
was	O
the	O
median	B-SecondaryOutcome
time	I-SecondaryOutcome
to	I-SecondaryOutcome
SARS	I-SecondaryOutcome
-	I-SecondaryOutcome
CoV	I-SecondaryOutcome
-	I-SecondaryOutcome
2	I-SecondaryOutcome
clearance	I-SecondaryOutcome

